Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

NCT00297713 | Completed Phase 2

• 1 other identifier: 230-00009
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 3

Brief Summary

ALTU-238 is a long acting crystalline formulation of recombinant human growth hormone (rhGH) that is being developed for the treatment of growth hormone deficiency in adults and children. ALTU-238 is designed to require fewer injections than the currently available formulations of rhGH.

Conditions

Adult Growth Hormone Deficiency

Interventions

ALTU-238 DRUG

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Growth hormone deficient men and women ages 18-60 years with a hypothalamic and/or pituitary structural lesion or longstanding idiopathic GHD
• Growth hormone deficiency as determined by pituitary testing within the last five years by either of the two following tests:
• Insulin hypoglycemia (glucose \< 50 mg/dL) with maximum GH \< 5 ng/mL (5 µg/L) by radioimmunoassay or \< 2.5 µg/L, if measured by immunoradiometric assay
• Arginine-GHRH infusions with maximum GH \< 5 ng/mL (5 µg/L) or \< 2.5 µg/L, if measured by immunoradiometric assay
• Women must be of non-child bearing potential (hysterectomy, tubal ligation, or IUD are acceptable) during the three months prior to entering the study, or post-menopausal (no menses for one year or more), or six to twelve months without menses and β-estradiol levels \< 20 pg/mL
• Glucocorticoid use is allowed provided the subject has been on physiologic (\<7.5 mg prednisone or equivalent/day) replacement doses for at least 3 months
• Free thyroxine (T4) within the normal range at Screening. If the subject is receiving thyroid hormone replacement therapy, the dose must be stable for at least 6 weeks prior to Screening
• Willing and able to provide written informed consent
• BMI 20 - 36 kg/m2

You may not qualify if:

• Any previous or ongoing clinically significant illness that, in the opinion of the investigator, could prevent the subject from completing the study
• Any history of cancer within the past 5 years, except for dermal squamous and basal cell carcinoma with documented 6-month remission. Subjects with a more recent history of successfully treated cervical carcinoma in situ will not be excluded provided there is documented 12-month remission
• BMI \<20 or \>36 kg/m2
• Any allergic or abnormal reaction to human growth hormone
• Inability of the subject to discontinue use of their regularly prescribed human growth hormone treatment from six weeks prior to Day -1 through the completion of the study
• Serum creatinine \> 1.4 mg/dL
• Hypocalcemia or hypercalcemia from any cause
• Hyperparathyroidism, osteomalacia or any other disorder which may affect bone and bone markers including the use of bisphosphonates or other medications for osteoporosis
• Participation in another clinical trial 30 days prior to screening
• Demonstrated inability to comply with protocol requirements (e.g. uncooperative attitude, inability to return for follow-up visits, history of medical non-compliance, and/or poor likelihood of completing the study)
• Blood donation within 56 days of the screening visit
• Plasma donation within seven days of the screening visit
• Positive serum pregnancy test
• Women of child bearing potential
• Abuse of alcohol; to be determined by principal investigator

Sponsors & Collaborators

• Altus Pharmaceuticals: lead

Study Sites (3)

University of Louisville

Louisville, Kentucky, 40202, United States

Location

University of Texas Medical Branch

Galveston, Texas, 77555, United States

Location

Diabetes and Glandular Disease Clinic

San Antonio, Texas, 78229, United States

Location

MeSH Terms

Conditions

Dwarfism, Pituitary

Condition Hierarchy (Ancestors)

Dwarfism; Bone Diseases, Developmental; Bone Diseases; Musculoskeletal Diseases; Bone Diseases, Endocrine; Hypopituitarism; Pituitary Diseases; Hypothalamic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: February 27, 2006
• First Posted: March 1, 2006
• Study Start: July 1, 2005
• Study Completion: June 1, 2006
• Last Updated: December 13, 2006

Record last verified: 2006-12

Locations

US (3)